Comvita’s balance sheet reset opens a tougher test for profitable growth

Balance Sheet Reset Creates Room for Comvita’s Next Act

Comvita Limited (NZX:CVT) has completed the most important part of its recovery plan: it has bought time. The Mānuka honey company ended FY26 with NZ$0.5 million of net cash, compared with NZ$62.4 million of net debt a year earlier, after a NZ$40.5 million recapitalisation and refinancing of its bank facilities through to September 2028.

The improvement was not confined to the balance sheet. FY26 net profit after tax returned to NZ$7.7 million from a NZ$104.8 million loss, operating profit reached NZ$14.0 million and free cash flow was NZ$30.3 million. Inventory fell to NZ$79.9 million, while management said revenue grew 10.7%, gross profit increased 38.8% and operating expenses were reduced by NZ$12.2 million. The earlier NZ$40.5 million capital raise had brought F&N Ventures on board as a near-20% strategic investor.

First-Quarter Sales Rise as Guidance Waits

Chief executive Karl Gradon told shareholders that unaudited group sales in the first quarter of FY27 rose 4.6% from the same period a year earlier. Gross margin percentage improved, and Comvita said premium pricing, cost control and foreign-exchange tailwinds were helping offset pressure on honey pricing. Excluding foreign exchange, profitability was described as in line with the prior year.

That is a positive start, but it is not yet a full-year forecast. Comvita is withholding FY27 guidance until it has made decisions on markets, channels and its operating model, with guidance expected ahead of or alongside the February half-year result. Management cited the Mānuka honey season, key gifting periods, macroeconomic and geopolitical conditions, and foreign exchange as variables still being assessed.

Mānuka Strategy Shifts Towards Focus and Differentiation

Comvita’s strategy is becoming more selective. North America is now described as the largest Mānuka honey market, with strong momentum but intense e-commerce competition. In China, where Comvita said it retains more than 50% market share, softer demand and greater consumer price sensitivity are pushing the company towards premium grades, new formats and a tighter channel mix.

The company’s four priorities are to win in selected markets and channels, strengthen brand and innovation, simplify its operating model, and optimise capital and supply. Management highlighted Lepteridine, its proprietary gut-health science claim, as one route to sharper product differentiation, while also pointing to potential collaboration with F&N across distribution, manufacturing, supply chain, science and packaging. Those opportunities remain early-stage rather than quantified earnings contributions.

No FY27 Dividend as Cash Is Reinvested

Shareholders should not expect a cash return from FY27: Comvita said it does not currently expect to pay a dividend for the year. Gradon linked that position to the recapitalisation and the need to fund changes intended to rebuild earnings. Dividends, he said, will return when earnings, cash generation and the balance sheet can support them sustainably.

The trade-off is clear. Comvita has repaired its finances, but the next phase demands proof that the new operating model can produce consistent profit rather than a single-year rebound assisted by inventory reduction and other reset measures. The company itself acknowledged that revenue performance has not translated sufficiently into shareholder returns.

Board Contest Leaves Governance Questions Open

“Ms Bridget Coates is an independent director, who has served as a director since October 2021 and was appointed Chair of the Board on 31 August 2024.”

The annual meeting also put the post-recapitalisation board to a significant shareholder vote. Proxy figures supported the elections of Michael Sang, Michael Chye, Peter Nathan and Julia Xu, while Kosit Suksingha, the shareholder-nominated candidate, had 52.70% support. Removal proposals for Robert Major and Gregor Barclay recorded 56.20% and 53.68% support respectively, while the proposal to remove chair Bridget Coates had 17.60% support.

Shareholders also gave 65.54% support in the reported proxies for increasing total annual director remuneration from NZ$610,000 to NZ$850,000. Those figures are proxy votes received in the presentation, not a certified final results notice, so the resulting board composition and committee changes remain the immediate governance detail to confirm. The contested agenda had been flagged in the three director removal proposals, making the vote more than a routine annual-meeting exercise.